Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 28, 2026, 1:34 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Type Two Diabetes Mellitus Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Insulin Degludec/Insulin Aspart in Insulin-naïve Subjects With Type 2 Diabetes Using Two Dosing Regimens

NCT01365507
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin degludec/insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
276 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
25
States / cities
Concord, California • Los Angeles, California • Montclair, California + 20 more
Source: ClinicalTrials.gov public record
Updated Mar 16, 2017 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)

NCT04848480
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
insulin icodec, insulin degludec, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
582 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
42
States / cities
Concord, California • Escondido, California • Fresno, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

A Concordance Study Comparing Insulin Treatments in Patients With Type 2 Diabetes

NCT00330473
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Human Insulin Inhalation Powder, Insulin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,019 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
24
States / cities
Huntington Beach, California • Pomona, California • Jacksonville, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2019 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

Randomized, Placebo-controlled, 2 Period, Single-blind, Sequential, Multiple Ascending Dose Study

NCT01956305
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
DS-7309, placebo, Metformin
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2014 · Synced Sep 28, 2026, 1:34 PM EDT
Active, not recruiting Phase 4 Interventional

Teplizumab in Pediatric Stage 2 Type 1 Diabetes

NCT05757713
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
teplizumab
Biological
Lead sponsor
Sanofi
Industry
Eligibility
0 Years to 7 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
10
States / cities
San Francisco, California • Aurora, Colorado • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2026 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 2 Interventional Results available

A Research Study to Compare Two Types of Insulin: Insulin 287 and Insulin Glargine in People With Type 2 Diabetes Who Have Not Used Insulin Before

NCT03951805
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin icodec, Insulin Glargine
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 75 Years
Enrollment
205 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
12
States / cities
Anaheim, California • Lancaster, California • Roswell, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2021 · Synced Sep 28, 2026, 1:34 PM EDT
Recruiting Not applicable Interventional

Implementation of Team Clinic for Type 2 Diabetes (TCT2)

NCT06923046
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Standard of Care, Shared Medical Appointments
Other · Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
12 Years to 18 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
2
States / cities
Los Angeles, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Not applicable Interventional

Fit for Two: Incorporating Wearable Trackers Into Clinical Care for Pregnant Women With Diabetes (FFT)

NCT03302377
View directory record Official record
Conditions
Physical Activity, Type 2 Diabetes Mellitus
Interventions
physical activity counseling & Fitbit
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

Extension Study for 2993-112

NCT01789957
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
AC2993
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
219
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 162 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Sep 28, 2026, 1:34 PM EDT
Recruiting Phase 3 Interventional

Comparative Effectiveness of Two Initial Combination Therapies in Patients With Recent Onset Diabetes

NCT06246799
View directory record Official record
Conditions
Type 2 Diabetes (Adult Onset)
Interventions
Tirzepatide, Pioglitazone, Sitagliptin, Metformin HCI XR
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years to 75 Years
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
2
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate Multiple Ascending Doses and Relative Bioavailability of AZD5004 in Healthy Participants

NCT06555822
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5004, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 16, 2025 · Synced Sep 28, 2026, 1:34 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus

NCT02239354
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
VC-01™ Combination Product
Combination Product
Lead sponsor
ViaCyte
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 23, 2022 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 1 Interventional

Pharmacokinetic Profile of Two Formulations of PB1023 Following Single Subcutaneous Injection in Subjects With Type 2 Diabetes Mellitus

NCT01427257
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Single Dose PB1023
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Results available

Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes

NCT00537303
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
insulin detemir, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
20
States / cities
Fresno, California • Mission Viejo, California • Miami, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 28, 2026, 1:34 PM EDT
Terminated Phase 4 Interventional Results available

A Clinical Trial Comparing Efficacy and Safety of Exubera® and Humalog®

NCT00356421
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Inhaled Human Insulin (Exubera®), Insulin lispro (Humalog)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Hamilton, New Jersey • New Brunswick, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 1, 2009 · Synced Sep 28, 2026, 1:34 PM EDT
Completed No phase listed Observational

Relationship Between Changes in Gut Hormones After Gastric Bypass and Gastric Banding and Improvements in Diabetes

NCT01153438
View directory record Official record
Conditions
Type 2 Diabetes, Obesity, Bariatric Surgery
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2016 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 4 Interventional Results available

Insulin Glulisine in Type 2 Diabetic Patients

NCT00360698
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Glargine, Glimepiride, Insulin Glulisine, Metformin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 75 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 7, 2011 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 4 Interventional

Comparison of Glycemic Control Achieved With 2 Different Needles

NCT00572052
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Delivery Systems
Interventions
NovoFine® needle 6 mm, Ultra-Fine needle 12.7 mm
Device
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 60 Years
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
5
States / cities
Walnut Creek, California • Berlin, New Jersey • Lawrenceville, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2017 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Drug to Drug Interaction Study of Sotagliflozin With Hydrochlorothiazide

NCT03387657
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin (SAR439954), Hydrochlorothiazide
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 24, 2022 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 3 Interventional

Evaluation of the Effect on Glucose Control of AC2993 in Patients With Type 2 Diabetes Mellitus Treated With a Sulfonylurea

NCT00039026
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
AC2993, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
16 Years to 75 Years
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
126
States / cities
Anniston, Alabama • Birmingham, Alabama • Eclectic, Alabama + 99 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2015 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 4 Interventional

Evaluation of the Safety Use of the InsuPatch Device in Daily Life Conditions

NCT01283425
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
InsuPatch
Device
Lead sponsor
Insuline Medical Ltd.
Industry
Eligibility
18 Years to 65 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
San Mateo, California
Source: ClinicalTrials.gov public record
Updated Sep 3, 2014 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Type 2 Diabetes Mellitus

NCT01064687
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
LY2189265, Exenatide, Placebo, Metformin, Pioglitazone
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
978 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
78
States / cities
Goodyear, Arizona • Phoenix, Arizona • Cathedral City, California + 75 more
Source: ClinicalTrials.gov public record
Updated Jan 25, 2015 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Phase 4 Interventional

Study to Estimate the Effects of Inhaled Versus Intravenous (IV) Infusion of Human Insulin in Subjects With Type 1 Diabetes

NCT00315952
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Exubera
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years to 50 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2008 · Synced Sep 28, 2026, 1:34 PM EDT
Completed Not applicable Interventional

Evaluation of the Impact of a Food is Medicine Program on Diabetes-related Health Outcomes for People With Type 2 Diabetes in a Low Income Community-based Setting Compared to Usual Care

NCT07529184
View directory record Official record
Conditions
Diabetes (DM)
Interventions
Food is medicine
Dietary Supplement
Lead sponsor
Public Health Institute Center for Wellness and Nutrition
Other
Eligibility
18 Years and older
Enrollment
405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Sep 28, 2026, 1:34 PM EDT